Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real‐life Italian tertiary centre experience
- 20 January 2020
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (8) , E380-E383
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 7‐10% of adults1. The systemic treatment for moderate‐to‐severe AD was limited, but a new biologic drug (Dupilumab) was recently approved. It is a fully human monoclonal antibody directed against the alpha‐subunit of the interleukin‐4‐receptor, blocking signalling of both Th2‐cytokines IL‐4 and IL‐13. The effectiveness and safety was demonstrated in clinical trials2‐4, but these studies do not reflect conditions in daily practice.Keywords
This publication has 10 references indexed in Scilit:
- Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitisJournal of Dermatological Treatment, 2019
- Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohortJournal of the American Academy of Dermatology, 2019
- Treatment of moderate‐to‐severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case seriesBritish Journal of Dermatology, 2019
- Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centreJournal of the European Academy of Dermatology and Venereology, 2019
- Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real‐life practiceBritish Journal of Dermatology, 2019
- Atopic dermatitisNature Reviews Disease Primers, 2018
- Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part IJournal of the European Academy of Dermatology and Venereology, 2018
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical tBritish Journal of Dermatology, 2017
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016